

# Oronzo Brunetti

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/5752805/oronzo-brunetti-publications-by-year.pdf>

**Version:** 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

105  
papers

1,639  
citations

25  
h-index

35  
g-index

123  
ext. papers

2,243  
ext. citations

5.1  
avg. IF

4.8  
L-index

| #   | Paper  | IF  | Citations |
|-----|--|-----|-----------|
| 105 | Prediction and validation of GUCA2B as the hub-gene in colorectal cancer based on co-expression network analysis: In-silico and in-vivo study.. <i>Biomedicine and Pharmacotherapy</i> , <b>2022</b> , 147, 112691   | 7.5 | 0         |
| 104 | The cross-talk between tumor-associated macrophages and tumor endothelium: Recent advances in macrophage-based cancer immunotherapy.. <i>Biomedicine and Pharmacotherapy</i> , <b>2022</b> , 146, 112588   | 7.5 | 1         |
| 103 | Identification of Common and Distinct Pathways in Inflammatory Bowel Disease and Colorectal Cancer: A Hypothesis Based on Weighted Gene Co-Expression Network Analysis.. <i>Frontiers in Genetics</i> , <b>2022</b> , 13, 848646                                     | 4.5 | 0         |
| 102 | The regulatory role of autophagy-related miRNAs in lung cancer drug resistance.. <i>Biomedicine and Pharmacotherapy</i> , <b>2022</b> , 148, 112735  | 7.5 | 4         |
| 101 | The role of immune checkpoint inhibitors in the treatment sequence of advanced gastric or gastro-esophageal junction cancer: A systematic review and meta-analysis of randomized trials.. <i>Critical Reviews in Oncology/Hematology</i> , <b>2022</b> , 173, 103674 | 7   | 0         |
| 100 | Targeted Therapy of B7 Family Checkpoints as an Innovative Approach to Overcome Cancer Therapy Resistance: A Review from Chemotherapy to Immunotherapy. <i>Molecules</i> , <b>2022</b> , 27, 3545  | 4.8 |           |
| 99  | Evolving pancreatic cancer treatment: From diagnosis to healthcare management.. <i>Critical Reviews in Oncology/Hematology</i> , <b>2021</b> , 169, 103571   | 7   | 2         |
| 98  | A Systematic Review on PD-1 Blockade and PD-1 Gene-Editing of CAR-T Cells for Glioma Therapy: From Deciphering to Personalized Medicine.. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 788211  | 8.4 | 0         |
| 97  | Silencing tumor-intrinsic CD73 enhances the chemosensitivity of NSCLC and potentiates the anti-tumoral effects of cisplatin: An in vitro study. <i>Biomedicine and Pharmacotherapy</i> , <b>2021</b> , 145, 112370   | 7.5 | 0         |
| 96  | A Promising Role of TGF- $\beta$ Pathway in Response to Regorafenib in Metastatic Colorectal Cancer: A Case Report. <i>Medicina (Lithuania)</i> , <b>2021</b> , 57,  | 3.1 | 0         |
| 95  | Immunotherapy of cancer in single-cell RNA sequencing era: A precision medicine perspective.. <i>Biomedicine and Pharmacotherapy</i> , <b>2021</b> , 146, 112558   | 7.5 | 1         |
| 94  | The importance of immune checkpoints in immune monitoring: A future paradigm shift in the treatment of cancer.. <i>Biomedicine and Pharmacotherapy</i> , <b>2021</b> , 146, 112516   | 7.5 | 7         |
| 93  | Hepatocellular Cancer. <i>UNIPA Springer Series</i> , <b>2021</b> , 689-706  | 0.1 | 0         |
| 92  | The Positive and Negative Immunoregulatory Role of B7 Family: Promising Novel Targets in Gastric Cancer Treatment. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,  | 6.3 | 6         |
| 91  | Cholangiocarcinoma: new perspectives for new horizons. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2021</b> , 1-17  | 4.2 | 0         |
| 90  | Lights and Shadows on Managing Immune Checkpoint Inhibitors in Oncology during the COVID-19 Era. <i>Cancers</i> , <b>2021</b> , 13,  | 6.6 | 1         |
| 89  | The Role of V-Domain Ig Suppressor of T Cell Activation (VISTA) in Cancer Therapy: Lessons Learned and the Road Ahead. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 676181   | 8.4 | 8         |

|    |   |     |    |
|----|---|-----|----|
| 88 | Cytotoxic T-Lymphocyte Antigen-4 in Colorectal Cancer: Another Therapeutic Side of Capecitabine. <i>Cancers</i> , <b>2021</b> , 13,   | 6.6 | 22 |
| 87 | The combination effect of Prominin1 (CD133) suppression and Oxaliplatin treatment in colorectal cancer therapy. <i>Biomedicine and Pharmacotherapy</i> , <b>2021</b> , 137, 111364  | 7.5 | 5  |
| 86 | Second-line treatments for Advanced Hepatocellular Carcinoma: A Systematic Review and Bayesian Network Meta-analysis. <i>Clinical and Experimental Medicine</i> , <b>2021</b> , 1   | 4.9 | 8  |
| 85 | Effects of Metformin and Vitamin D on Clinical Outcome in Cholangiocarcinoma Patients. <i>Oncology</i> , <b>2021</b> , 99, 292-299  | 3.6 | 3  |
| 84 | COVID Vaccination in Cancer Patients: What Vaccination Priority Strategies Should There Be?. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 641388  | 5.3 | 6  |
| 83 | Extensive molecular reclassification: new perspectives in small bowel adenocarcinoma?. <i>Medical Oncology</i> , <b>2021</b> , 38, 17   | 3.7 |    |
| 82 | Clinical insights and prognostic factors from an advanced biliary tract cancer case series: a real-world analysis. <i>Journal of Chemotherapy</i> , <b>2021</b> , 1-10  | 2.3 | 0  |
| 81 | A Systematic Review to Clarify the Prognostic Values of CD44 and CD44CD24 Phenotype in Triple-Negative Breast Cancer Patients: Lessons Learned and The Road Ahead. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 689839                          | 5.3 | 0  |
| 80 | Immune Checkpoint Inhibitors in Colorectal Cancer: Challenges and Future Prospects. <i>Biomedicines</i> , <b>2021</b> , 9,  | 4.8 | 7  |
| 79 | A Systematic Review on the Therapeutic Potentiality of PD-L1-Inhibiting MicroRNAs for Triple-Negative Breast Cancer: Toward Single-Cell Sequencing-Guided Biomimetic Delivery. <i>Genes</i> , <b>2021</b> , 12,                                     | 4.2 | 9  |
| 78 | A Systematic Review of the Tumor-Infiltrating CD8 T-Cells/PD-L1 Axis in High-Grade Glial Tumors: Toward Personalized Immuno-Oncology. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 734956   | 8.4 | 2  |
| 77 | A Systematic Review and Meta-Analysis on the Significance of TIGIT in Solid Cancers: Dual TIGIT/PD-1 Blockade to Overcome Immune-Resistance in Solid Cancers. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,                | 6.3 | 2  |
| 76 | Regulation of immune responses through CD39 and CD73 in cancer: Novel checkpoints. <i>Life Sciences</i> , <b>2021</b> , 282, 119826   | 6.8 | 9  |
| 75 | A scoping review on the potentiality of PD-L1-inhibiting microRNAs in treating colorectal cancer: Toward single-cell sequencing-guided biocompatible-based delivery. <i>Biomedicine and Pharmacotherapy</i> , <b>2021</b> , 143, 112213             | 7.5 | 2  |
| 74 | MicroRNAs and lncRNAs-A New Layer of Myeloid-Derived Suppressor Cells Regulation. <i>Frontiers in Immunology</i> , <b>2020</b> , 11, 572323   | 8.4 | 10 |
| 73 | Anti-angiogenesis and Immunotherapy: Novel Paradigms to Envision Tailored Approaches in Renal Cell-Carcinoma. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,  | 5.1 | 23 |
| 72 | Expression and characterization of a novel recombinant cytotoxin II from <i>Naja naja oxiana</i> venom: A potential treatment for breast cancer. <i>International Journal of Biological Macromolecules</i> , <b>2020</b> , 162, 1283-1292           | 7.9 | 2  |
| 71 | Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up of Exocrine Pancreatic Ductal Adenocarcinoma: Evidence Evaluation and Recommendations by the Italian Association of Medical Oncology (AIOM). <i>Cancers</i> , <b>2020</b> , 12, | 6.6 | 9  |

|    |  |     |    |
|----|--|-----|----|
| 70 | Basics and Frontiers on Pancreatic Cancer for Radiation Oncology: Target Delineation, SBRT, SIB technique, MRgRT, Particle Therapy, Immunotherapy and Clinical Guidelines. <i>Cancers</i> , <b>2020</b> , 12,                        | 6.6 | 12 |
| 69 | Combination of Ipilimumab and Nivolumab in Cancers: From Clinical Practice to Ongoing Clinical Trials. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,  | 6.3 | 28 |
| 68 | Moving the Target on the Optimal Adjuvant Strategy for Resected Pancreatic Cancers: A Systematic Review with Meta-Analysis. <i>Cancers</i> , <b>2020</b> , 12,   | 6.6 | 8  |
| 67 | Pancreatic Enzyme Replacement Therapy in Pancreatic Cancer. <i>Cancers</i> , <b>2020</b> , 12,   | 6.6 | 26 |
| 66 | MiR-144: A New Possible Therapeutic Target and Diagnostic/Prognostic Tool in Cancers. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,   | 6.3 | 15 |
| 65 | COVID-19 Infection in Cancer Patients: How Can Oncologists Deal With These Patients?. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 734   | 5.3 | 29 |
| 64 | Immune system and bone microenvironment: rationale for targeted cancer therapies. <i>Oncotarget</i> , <b>2020</b> , 11, 480-487  | 3.3 | 24 |
| 63 | Is it Time for a Therapeutic Algorithm in Resected Pancreatic Ductal Adenocarcinoma?. <i>Pancreas</i> , <b>2020</b> , 49, e11  | 2.6 |    |
| 62 | NLRP3 Inflammasome From Bench to Bedside: New Perspectives for Triple Negative Breast Cancer. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 1587  | 5.3 | 9  |
| 61 | Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma. <i>Targeted Oncology</i> , <b>2020</b> , 15, 773-785  | 5   | 8  |
| 60 | The Latest Findings of PD-1/PD-L1 Inhibitor Application in Gynecologic Cancers. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,   | 6.3 | 17 |
| 59 | Immune Checkpoints and CAR-T Cells: The Pioneers in Future Cancer Therapies?. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,   | 6.3 | 22 |
| 58 | Targeting TGF- $\beta$ Mediated SMAD Signaling Pathway via Novel Recombinant Cytotoxin II: A Potent Protein from Venom in Melanoma. <i>Molecules</i> , <b>2020</b> , 25,   | 4.8 | 7  |
| 57 | Complete Response of Synchronous Liver Metastasis in a Pancreatic Ductal Adenocarcinoma, When Surgery Could Represent a Therapeutic Option. <i>Canadian Journal of Gastroenterology and Hepatology</i> , <b>2020</b> , 2020, 8679751 | 2.8 | 0  |
| 56 | Coronavirus Disease 2019: A Brief Review of the Clinical Manifestations and Pathogenesis to the Novel Management Approaches and Treatments. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 572329                                  | 5.3 | 3  |
| 55 | On the Management of Drug Interactions in the Course of Concomitant Treatments for COVID-19 and Antineoplastic Agents. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 1340   | 5.3 | 3  |
| 54 | Somatic BRCA Mutation in a Cholangiocarcinoma Patient for HBOC Syndrome Detection. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 1292   | 5.3 | 2  |
| 53 | Skeletal Metastases of Unknown Primary: Biological Landscape and Clinical Overview. <i>Cancers</i> , <b>2019</b> , 11,   | 6.6 | 14 |

|    |   |     |    |
|----|---|-----|----|
| 52 | Molecular Characterization of a Long-Term Survivor Double Metastatic Non-Small Cell Lung Cancer and Pancreatic Ductal Adenocarcinoma Treated with Gefitinib in Combination with Gemcitabine Plus Nab-Paclitaxel and mFOLFOX6 as First and Second Line Therapy. <i>Cancers</i> , <b>2019</b> , 11,                     | 6.6 | 3  |
| 51 | Management of targeted therapies in cancer patients with chronic kidney disease, or on haemodialysis: An Associazione Italiana di Oncologia Medica (AIOM)/Societa' Italiana di Nefrologia (SIN) multidisciplinary consensus position paper. <i>Critical Reviews in Oncology/Hematology</i> , <b>2019</b> , 140, 39-51 | 7   | 7  |
| 50 | Strategies to Improve Cancer Immune Checkpoint Inhibitors Efficacy, Other Than Abscopal Effect: A Systematic Review. <i>Cancers</i> , <b>2019</b> , 11,   | 6.6 | 32 |
| 49 | Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations. <i>European Journal of Cancer</i> , <b>2019</b> , 111, 94-106  | 7.5 | 25 |
| 48 | CAFs and TGF- $\beta$ Signaling Activation by Mast Cells Contribute to Resistance to Gemcitabine/Nabpaclitaxel in Pancreatic Cancer. <i>Cancers</i> , <b>2019</b> , 11,   | 6.6 | 55 |
| 47 | The Italian Rare Pancreatic Exocrine Cancer Initiative. <i>Tumori</i> , <b>2019</b> , 105, 353-358  | 1.7 | 3  |
| 46 | Inflammatory cells infiltrate and angiogenesis in locally advanced and metastatic cholangiocarcinoma. <i>European Journal of Clinical Investigation</i> , <b>2019</b> , 49, e13087  | 4.6 | 16 |
| 45 | Gene Expression Comparison between the Lymph Node-Positive and -Negative Reveals a Peculiar Immune Microenvironment Signature and a Theranostic Role for WNT Targeting in Pancreatic Ductal Adenocarcinoma: A Pilot Study. <i>Cancers</i> , <b>2019</b> , 11,   | 6.6 | 55 |
| 44 | Emerging role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma. <i>Medicina (Lithuania)</i> , <b>2019</b> , 55,  | 3.1 | 31 |
| 43 | Bone metastasis as primary presentation of pancreatic ductal adenocarcinoma: A case report and literature review. <i>Clinical Case Reports (discontinued)</i> , <b>2019</b> , 7, 1972-1976  | 0.7 | 7  |
| 42 | Systematic Review of Irreversible Electroporation Role in Management of Locally Advanced Pancreatic Cancer. <i>Cancers</i> , <b>2019</b> , 11,  | 6.6 | 15 |
| 41 | Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib. <i>Medicina (Lithuania)</i> , <b>2019</b> , 55,   | 3.1 | 36 |
| 40 | Long-term survival of an advanced colorectal cancer patient treated with Regorafenib: Case report and literature review. <i>Clinical Case Reports (discontinued)</i> , <b>2019</b> , 7, 2379-2383   | 0.7 | 5  |
| 39 | Role of BRAF in Hepatocellular Carcinoma: A Rationale for Future Targeted Cancer Therapies. <i>Medicina (Lithuania)</i> , <b>2019</b> , 55,   | 3.1 | 33 |
| 38 | Mast cells and angiogenesis in pancreatic ductal adenocarcinoma. <i>Clinical and Experimental Medicine</i> , <b>2018</b> , 18, 319-323  | 4.9 | 17 |
| 37 | Bone metastases in biliary cancers: A multicenter retrospective survey. <i>Journal of Bone Oncology</i> , <b>2018</b> , 12, 33-37   | 4.5 | 2  |
| 36 | Immunological mutational signature in adenosquamous cancer of pancreas: an exploratory study of potentially therapeutic targets. <i>Expert Opinion on Therapeutic Targets</i> , <b>2018</b> , 22, 453-461   | 6.4 | 8  |
| 35 | Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol. <i>Tumori</i> , <b>2018</b> , 104, 476-479  | 1.7 | 12 |

|    |  |     |    |
|----|--|-----|----|
| 34 | Systemic Chemotherapy for Advanced Rare Pancreatic Histotype Tumors: A Retrospective Multicenter Analysis. <i>Pancreas</i> , <b>2018</b> , 47, 759-771   | 2.6 | 20 |
| 33 | Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: a retrospective study. <i>Scientific Reports</i> , <b>2017</b> , 7, 42499  | 4.9 | 25 |
| 32 | Multimodal treatment of resectable pancreatic ductal adenocarcinoma. <i>Critical Reviews in Oncology/Hematology</i> , <b>2017</b> , 111, 152-165   | 7   | 26 |
| 31 | Second-line chemotherapy for advanced pancreatic cancer: Which is the best option?. <i>Critical Reviews in Oncology/Hematology</i> , <b>2017</b> , 115, 1-12   | 7   | 20 |
| 30 | Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors. <i>Cancer Medicine</i> , <b>2017</b> , 6, 1493-1499   | 4.8 | 9  |
| 29 | Immunotherapy for colorectal cancer: where are we heading?. <i>Expert Opinion on Biological Therapy</i> , <b>2017</b> , 17, 709-721  | 5.4 | 71 |
| 28 | Selecting patients for gastrectomy in metastatic esophago-gastric cancer: clinics and pathology are not enough. <i>Future Oncology</i> , <b>2017</b> , 13, 2265-2275   | 3.6 | 8  |
| 27 | Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale. <i>European Journal of Cancer</i> , <b>2017</b> , 86, 106-114              | 7.5 | 54 |
| 26 | Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma. <i>Targeted Oncology</i> , <b>2017</b> , 12, 795-803   | 5   | 20 |
| 25 | Management of patients with end-stage renal disease undergoing chemotherapy: recommendations of the Associazione Italiana di Oncologia Medica (AIOM) and the Società Italiana di Nefrologia (SIN). <i>ESMO Open</i> , <b>2017</b> , 2, e000167 | 6   | 14 |
| 24 | Immunotherapeutic approaches for hepatocellular carcinoma. <i>Oncotarget</i> , <b>2017</b> , 8, 33897-33910  | 3.3 | 45 |
| 23 | Targeting Angiogenesis in Biliary Tract Cancers: An Open Option. <i>International Journal of Molecular Sciences</i> , <b>2017</b> , 18,  | 6.3 | 33 |
| 22 | Antiangiogenic agents after first line and sorafenib plus chemoembolization: a systematic review. <i>Oncotarget</i> , <b>2017</b> , 8, 66699-66708   | 3.3 | 11 |
| 21 | Angiogenesis in adenosquamous cancer of pancreas. <i>Oncotarget</i> , <b>2017</b> , 8, 95773-95779   | 3.3 | 15 |
| 20 | The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy. <i>Scientific Reports</i> , <b>2016</b> , 6, 24136   | 4.9 | 16 |
| 19 | Role of miR-27a, miR-181a and miR-20b in gastric cancer hypoxia-induced chemoresistance. <i>Cancer Biology and Therapy</i> , <b>2016</b> , 17, 400-6   | 4.6 | 57 |
| 18 | Neoadjuvant multimodal treatment of pancreatic ductal adenocarcinoma. <i>Critical Reviews in Oncology/Hematology</i> , <b>2016</b> , 98, 309-24  | 7   | 30 |
| 17 | Total and not bevacizumab-bound vascular endothelial growth factor as potential predictive factors to bevacizumab-based chemotherapy in colorectal cancer. <i>World Journal of Gastroenterology</i> , <b>2016</b> , 22, 6287-95                | 5.6 | 6  |

|    |   |      |    |
|----|---|------|----|
| 16 | Innovative surgical approaches for hepatocellular carcinoma. <i>World Journal of Hepatology</i> , <b>2016</b> , 8, 591-604  | 6.4  | 17 |
| 15 | Potential predictive role of chemotherapy-induced changes of soluble CD40 ligand in untreated advanced pancreatic ductal adenocarcinoma. <i>Oncotargets and Therapy</i> , <b>2016</b> , 9, 4681-6                                     | 4.4  | 7  |
| 14 | Angiogenesis in pancreatic ductal adenocarcinoma: A controversial issue. <i>Oncotarget</i> , <b>2016</b> , 7, 58649-58658   | 5.8  | 54 |
| 13 | The Immune Revolution in Gastrointestinal Tumours: Leading the Way or Just Following?. <i>Targeted Oncology</i> , <b>2016</b> , 11, 593-603   | 5    | 12 |
| 12 | The potential predictive role of nuclear NHERF1 expression in advanced gastric cancer patients treated with epirubicin/oxaliplatin/capecitabine first line chemotherapy. <i>Cancer Biology and Therapy</i> , <b>2015</b> , 16, 1140-7 | 4.6  | 11 |
| 11 | Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib. <i>Expert Opinion on Pharmacotherapy</i> , <b>2015</b> , 16, 2719-25   | 4    | 51 |
| 10 | Hepatocellular carcinoma treatment over sorafenib: epigenetics, microRNAs and microenvironment. Is there a light at the end of the tunnel?. <i>Expert Opinion on Therapeutic Targets</i> , <b>2015</b> , 19, 1623-35                  | 6.4  | 55 |
| 9  | Everolimus restrains the paracrine pro-osteoclast activity of breast cancer cells. <i>BMC Cancer</i> , <b>2015</b> , 15, 692  | 4.8  | 15 |
| 8  | MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic targets?. <i>Oncotarget</i> , <b>2015</b> , 6, 23323-41  | 3.3  | 55 |
| 7  | Paraneoplastic focal segmental glomerulosclerosis in sarcomatoid renal cell cancer. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, e66-70  | 2.2  | 2  |
| 6  | Bone metastases in hepatocellular carcinoma: an emerging issue. <i>Cancer and Metastasis Reviews</i> , <b>2014</b> , 33, 333-42   | 9.6  | 28 |
| 5  | Novel lenalidomide-based combinations for treatment of multiple myeloma. <i>Critical Reviews in Oncology/Hematology</i> , <b>2013</b> , 85, 9-20  | 7    | 9  |
| 4  | In vitro anti-myeloma activity of TRAIL-expressing adipose-derived mesenchymal stem cells. <i>British Journal of Haematology</i> , <b>2012</b> , 157, 586-98  | 4.5  | 40 |
| 3  | Therapeutic approaches to myeloma bone disease: an evolving story. <i>Cancer Treatment Reviews</i> , <b>2012</b> , 38, 787-97   | 14.4 | 24 |
| 2  | Immature dendritic cells from patients with multiple myeloma are prone to osteoclast differentiation in vitro. <i>Experimental Hematology</i> , <b>2011</b> , 39, 773-83.e1   | 3.1  | 32 |
| 1  | Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib  |      | 3  |